Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma

Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma Cardiovasc Intervent Radiol (2017) 40:1383–1391 DOI 10.1007/s00270-017-1648-7 CLINICAL INVESTIGATION INTERVENTIONAL ONCOLOGY Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma 1 1 2 1 • • • • Lauren S. Chan Daniel Y. Sze George A. Poultsides John D. Louie 1 1 Mohammed A. Abdelrazek Mohammed David S. Wang Received: 16 November 2016 / Accepted: 4 April 2017 / Published online: 21 April 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 Abstract before RE showed decreased levels after treatment (median Purpose Combined hepatocellular-cholangiocarcinoma decrease of 72%, range 13–80%). Best hepatic radiological (cHCC-CC) is a rare mixed cell type primary liver cancer response was 60% partial response and 40% stable disease with limited data to guide management. Transarterial by modified RECIST, and 100% stable disease by RECIST radioembolization with yttrium-90 microspheres (RE) is an v1.1. Poor performance status and the presence of emerging treatment option for both hepatocellular carci- macrovascular invasion were identified as predictors of noma and intrahepatic cholangiocarcinoma. This study reduced survival after RE. explored the safety and efficacy of RE for unre- Conclusion RE appears to be a safe and promising treat- sectable cHCC-CC. ment option for patients with unresectable cHCC-CC. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png CardioVascular and Interventional Radiology Springer Journals

Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma

Loading next page...
 
/lp/springer_journal/yttrium-90-radioembolization-for-unresectable-combined-hepatocellular-zxljDE4z7Q

References (43)

Publisher
Springer Journals
Copyright
Copyright © 2017 by Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE)
Subject
Medicine & Public Health; Imaging / Radiology; Cardiology; Nuclear Medicine; Ultrasound
ISSN
0174-1551
eISSN
1432-086X
DOI
10.1007/s00270-017-1648-7
pmid
28432387
Publisher site
See Article on Publisher Site

Abstract

Cardiovasc Intervent Radiol (2017) 40:1383–1391 DOI 10.1007/s00270-017-1648-7 CLINICAL INVESTIGATION INTERVENTIONAL ONCOLOGY Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma 1 1 2 1 • • • • Lauren S. Chan Daniel Y. Sze George A. Poultsides John D. Louie 1 1 Mohammed A. Abdelrazek Mohammed David S. Wang Received: 16 November 2016 / Accepted: 4 April 2017 / Published online: 21 April 2017 Springer Science+Business Media New York and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) 2017 Abstract before RE showed decreased levels after treatment (median Purpose Combined hepatocellular-cholangiocarcinoma decrease of 72%, range 13–80%). Best hepatic radiological (cHCC-CC) is a rare mixed cell type primary liver cancer response was 60% partial response and 40% stable disease with limited data to guide management. Transarterial by modified RECIST, and 100% stable disease by RECIST radioembolization with yttrium-90 microspheres (RE) is an v1.1. Poor performance status and the presence of emerging treatment option for both hepatocellular carci- macrovascular invasion were identified as predictors of noma and intrahepatic cholangiocarcinoma. This study reduced survival after RE. explored the safety and efficacy of RE for unre- Conclusion RE appears to be a safe and promising treat- sectable cHCC-CC. ment option for patients with unresectable cHCC-CC.

Journal

CardioVascular and Interventional RadiologySpringer Journals

Published: Apr 21, 2017

There are no references for this article.